http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9957251-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-3153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-166 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 1999-05-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_355f20528933f8721d384549206a9520 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf51bc67bbc85f451d6b1436ba3ad7a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26446039603b10d680353901c809c6cf |
| publicationDate | 1999-11-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9957251-A2 |
| titleOfInvention | Thrombolytic agents derived from streptokinase |
| abstract | Structural information about the streptokinase-micro plasminogen complex has been used to identify the part of the streptokinase structure not involved in plasminogen complexation or activation. These nonessential portions can be modified to reduce antigenicity, for example, by changing the nonessential portions of streptokinose to more human-like polypeptide portions ('humanization of streptokinase'). One way this can be done is to compare the nonessential portion to a structural database of human proteins to find similar structures. Then the streptokinase nonessential structural part is replaced with the human structural part such as by genetic engineering of a mutant encoding the individual streptokinases, which is then expressed in a bacterial host such as E. coli. Alternatively, the nonessential portions can be removed or truncated to simplify streptokinase to a smaller molecule which retains plasminogen activation activity. Such smaller proteins should have reduced antigenicity and be cheaper and easier to produce. The modified streptokinases are useful in treating clotting disorders. |
| priorityDate | 1998-05-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 134 of 134.